Esmolol 2500 Mg/10ml Ampoule
Orpha Swiss GmbH Switzerland flag Switzerland
Abstract ID:
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine.
Send an Inquiry
RE:
Participants
You

Esmolol is an ultra fast acting beta1-receptor blocker (cardio selective) with a very short elimination half-life of 9 minutes. This product is used for the short-term treatment of supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable (e.g. myocardial infarct). Target groups are anaesthetists and ICU-clinicians. Generic verion.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Country specific or regional distribution contract.

FEATURED
Last Updated Oct 2014
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION
Company Logo

Opportunity Contact